Engineered Macrophage Membrane‐Coated S100A9‐siRNA for Ameliorating Myocardial Ischemia‐Reperfusion Injury
Advanced Science · 2024
DOI: 10.1002/advs.202403542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von He Lu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing Drum Tower Hospital, Drum Tower Clinical College, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, 210008, China. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Calgranulin B, Disease Models, Animal, RNA, Small Interfering. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Science Fund for Distinguished Young Scholars in Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Despite the widespread adoption of emergency coronary reperfusion therapy, reperfusion‐induced myocardial injury remains a challenging issue in clinical practice. Following myocardial reperfusion, S100A8/A9 molecules are considered pivotal in initiating and regulating tissue inflammatory damage. Effectively reducing the S100A8/A9 level in ischemic myocardial tissue holds significant therapeutic value in salvaging damaged myocardium. In this study, HA (hemagglutinin)‐ and RAGE (receptor for advanced glycation end products)‐ comodified macrophage membrane‐coated siRNA nanoparticles (MMM/RNA NPs) with siRNA targeting S100A9 (S100A9‐siRNA) are successfully prepared. This nanocarrier system is able to target effectively the injured myocardium in an inflammatory environment while evading digestive damage by lysosomes. In vivo, migration of MMM/RNA NPs to myocardial injury lesions is confirmed in a myocardial ischemia‐reperfusion injury (MIRI) mouse model. Intravenous injection of MMM/RNA NPs significantly reduced S100A9 levels in serum and myocardial tissues, further decreasing myocardial infarction area and improving cardiac function. Targeted reduction of S100A8/A9 by genetically modified macrophage membrane‐coated nanoparticles may represent a new therapeutic intervention for MIRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanjing Drum Tower Hospital, Drum Tower Clinical College, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, 210008, China.
- Department of Cardiology, Affiliated Hospital of Nantong University, Nantong, 226001, China.
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing, 210008, China.
- Department of Cardiology, The People's Hospital of Jiawang District of Xuzhou, Xuzhou, 221011, China.
- Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing, 210008, China.
- Department of Cardiac Surgery, National Cardiovascular Disease Regional Center for Anhui, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
ORCID-Profile: Jun Xie
Förderung
- Natural Science Foundation of China
- Science Fund for Distinguished Young Scholars in Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Lu, H., Wang, J., Chen, Z., Wang, J., Jiang, Y., Xia, Z., Hou, Y., Shang, P., Li, R., Liu, Y., & Xie, J. (2024). Engineered Macrophage Membrane‐Coated S100A9‐siRNA for Ameliorating Myocardial Ischemia‐Reperfusion Injury. Advanced Science. https://doi.org/10.1002/advs.202403542
Vancouver
Lu H, Wang J, Chen Z, Wang J, Jiang Y, Xia Z, et al. Engineered Macrophage Membrane‐Coated S100A9‐siRNA for Ameliorating Myocardial Ischemia‐Reperfusion Injury. Advanced Science. 2024. doi:10.1002/advs.202403542
BibTeX
@article{Lu2024,
author = {Lu, He and Wang, Junzhuo and Chen, Ziwei and Wang, Jing and Jiang, Yaohui and Xia, Zequn and Hou, Ya and Shang, Pingping and Li, Rutian and Liu, Yuyong and Xie, Jun},
title = {Engineered Macrophage Membrane‐Coated S100A9‐siRNA for Ameliorating Myocardial Ischemia‐Reperfusion Injury},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202403542}
}
EUVIMED